Comparative Pharmacology
Head-to-head clinical analysis: IMKELDI versus ZYTIGA.
Head-to-head clinical analysis: IMKELDI versus ZYTIGA.
IMKELDI vs ZYTIGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imkelde (imipenem/cilastatin/relebactam) is a combination antibacterial agent. Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Cilastatin inhibits renal dehydropeptidase I, preventing renal metabolism of imipenem. Relebactam is a beta-lactamase inhibitor that protects imipenem from degradation by certain serine beta-lactamases, including KPC and some AmpC enzymes.
Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor that selectively inhibits the enzyme CYP17 (17α-hydroxylase/C17,20-lyase). This inhibition blocks androgen production in the testes, adrenal glands, and prostate tumor tissue.
10 mg orally once daily
1000 mg orally once daily on an empty stomach, at least 1 hour before or 2 hours after a meal, in combination with prednisone 5 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10-14 hours) in healthy adults; extended to 24-30 hours in moderate renal impairment (CrCl 30-50 mL/min). Clinical context: Steady state achieved after 3-4 days. Twice-daily dosing maintains therapeutic levels.
The terminal elimination half-life of abiraterone is approximately 12 hours (range 9–18 hours) following oral administration, supporting twice-daily dosing.
Primarily renal excretion of unchanged drug and metabolites; 70% recovered in urine (60% unchanged, 10% as glucuronide conjugate) and 30% in feces (mainly metabolites) over 72 hours.
Abiraterone is primarily eliminated via hepatic metabolism with less than 1% excreted unchanged in urine. Approximately 88% of a radiolabeled dose is recovered in feces (mainly as metabolites) and about 5% in urine.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent